English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In this study, the in vitro interaction of epirubicin (EPR), a cytostatic antibiotic, with plasma proteins (PP), namely α-HSA, γ-HSG, α+β-HSG and with isolated human red blood cells (RBCs) was investigated and further correlated with the in vivo pharmacokinetics and binding of EPR and two of its metabolites, 13-dihydroepirubicin and 7-deoxydoxorubicinone to RBCs. The in vitro encapsulation rate in isolated erythrocytes amounts to 52.9 ± 2.8% and remains constant within the range of studied concentrations (2.5-20 μg/ml). EPR was found to bind differently to the various PP in vitro. Binding to α-HSA amounted up to 51.0 ± 7.10%, to α + β-HSG 79.45 ± 2.7%, to γ-HSG 57.1 ± 2.8%. The in vivo-binding rate of EPR, dihydroepirubicin and deoxydoxorubicinone to RBCs after 5 min of injection was 32 ± 6.96%, 11.6 ± 3.1% and 10.05 ± 3.5% respectively, their availability in serum was 42.6 ± 11.8%, 2.4 ± 0.4% and 1.2 ± 0.67% respectively

In vitro and in vivo Binding of Epirubicin to Red Blood Cells and Human Plasma Proteins